Clinical Trial Update: Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Glenzocimab in SARS-CoV-2–associated acute respiratory distress syndrome (COVID-19).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome
• Sars-cov Infection

Drugs mentioned

• Glenzocimab (Glenzocimab)

Snippet

Sponsor: Acticor Biotech | Conditions: SARS-CoV Infection, Acute Respiratory Distress Syndrome | Phase 2 | Status: COMPLETED